Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Roche
- 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2017 Planned End Date changed from 1 Jun 2019 to 28 Jun 2019.
- 21 Mar 2017 Planned primary completion date changed from 1 Jun 2019 to 28 Jun 2019.